CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

Core Viewpoint - CRISPR Therapeutics AG has announced a private offering of $550 million in convertible senior notes due 2031, which was upsized from a previously announced $350 million offering [1][7] Group 1: Offering Details - The offering is targeted at qualified institutional buyers under Rule 144A of the Securities Act [1] - The notes will have an effective coupon of 1.125%, increased to 1.7308% due to anticipated Swiss tax withholding [2] - Interest payments will be made semiannually starting September 1, 2026, with maturity on March 1, 2031 [2] Group 2: Conversion and Redemption - Holders can convert their notes into common shares at a conversion rate of 13.0617 shares per $1,000 principal amount, equating to an initial conversion price of approximately $76.56 per share [3][4] - The conversion price represents a 45% premium over the last reported sale price of $52.80 per share on March 10, 2026 [4] - The company may redeem the notes starting March 6, 2029, under specific conditions related to the stock price [5] Group 3: Financial Proceeds and Use - The estimated net proceeds from the offering are approximately $536.3 million, or $585.2 million if the option for additional notes is fully exercised [7] - The proceeds will be used for general corporate purposes [7] Group 4: Company Overview - CRISPR Therapeutics is a leading biopharmaceutical company focused on gene-based medicines for serious diseases, with a notable achievement being the approval of CASGEVY, the first CRISPR-based therapy [10] - The company is advancing a diversified pipeline across various therapeutic areas and has established strategic collaborations with major biopharmaceutical partners [10]